医药代表:拜访受限的应对策略与关键行动计划

2020-02-12 枫叶的脚步 新浪医药新闻

没想到,灵性十足的鼠年给我们开启了这样一段新的年轮。2020年必将给我们每个人留下难以撩去的苦难记忆。对于医药代表来说,或是凛冽寒风中,自我洗礼后一次新的出发。

没想到,灵性十足的鼠年给我们开启了这样一段新的年轮。2020年必将给我们每个人留下难以撩去的苦难记忆。对于医药代表来说,或是凛冽寒风中,自我洗礼后一次新的出发。

为打赢这场战斗,绝大多数的医院临时关闭了很多门诊,病人尽可能选择网上问诊,减少去医院就诊的机会。这就意味着与疫情无关的专科处方药一季度乃至上半年将无法避免意料之外的下滑。

因此,当下医药代表面临的决策一定是集聚能量,做好充分的准备,一旦可冲出战壕,你的老板必将在后面猛抽鞭子,顶着你洒尽最后一滴汗水,没有第二条路可以选择。

鉴于上述,要努力做好以下几点,为自己赋能。

一,积极了解客户科室医护用品的紧急需求,如医用口罩、防护服、消毒水等

力尽所能,利用公司平台或个人当地的各种人脉资源,为他们提供暖心的帮助。患难之中见真情,为医护人员提供上战场的子弹,是值得大为称赞的行动计划。

二,Homebase期间,就像当年迎战高考一样,给自己制定一个可执行的产品知识学习计划

包括产品药理与作用机制,疗效与安全性数据。最重要的一点,要了解疾病治疗新进展以及临床难点与痛点,在此基础上,梳理出产品的优势与竞争机会。即使是仿制药,除了带量采购圈进的大品种,一些细分领域的小众仿制药仍需学习与挖掘。

但能沉下心来,努力学习产品知识的医药代表其实很少,绝大多数同学都牺牲在微信的碎片信息里了,如再沉迷在游戏里,学习就变异为“雾中花,镜中月”。我曾经有一次在复旦肿瘤医院楼下的KFC里,遇到邻座几个年轻人正在Role Play,他们谙熟产品研究的各种数据,对临床难点与痛点的把控、传递关键信息与异议的处理,让我发自内心地赞叹。其实医药代表的核心竞争力之一便是激励自己不断学习与提升。

三,基于以上积累,为客户提供有价值的专业服务

尤其是绝大多数副主任医师以下职称客户,他们有强烈的职称晋升与科研需求。利用知网,包括Pubmed等数据库的便利机会,帮助客户收集文献,并就文件的主要内容进行梳理归纳,帮助客户做好研究背景的文献准备工作。

另外客户手上有不少临床研究项目,由于CRC等工作不便,可在线帮助客户做一些力所能及的随访与数据整理。协助客户在线做好患者教育(直播、在线答疑、设计平面广告等)。能成为客户专业发展的小助手,再加上品德高雅,一定是客户倍加赞赏的优秀医药代表。

四,和领导一起对客户再进行一次深度梳理

包括客户对产品的疾病治疗认知,哪些疾病是客户比较认可的,哪些是持有怀疑态度的,哪些居然还是空白的,结合客户的门诊量与床位周转,确定客户的用药潜力;客户对公司与医药代表个人的认可程度,并分析出背后的深层次原因;客户的专业需求与情感需求是什么?其实,找不到客户需求的医药代表还是一个初级职称的菜鸟。研判竞争对手与客户的连接状况。

基于以上维度,再一次制定针对具体客户的产品推广策略。我认为这是医药代表当下比较重要的工作。优秀医药代表,客户在他们的心中,一定是鲜活的,有故事的,可敬可爱的,也很容易走进他们的内心,推广策略不需要写在纸上,它一定清晰流淌在自己的心田里。

五,微信拜访,打Call,这些都是常规动作

我这里就不费笔墨了。其实功夫在平时,走不进客户内心的医药代表,建议你这个时候少打扰客户,打扰产生负效应是大概率事件。这里我要提醒的是,大家一定要关注医院的最低库存,因为现在运输受限,不要在这个时候让患者断药。

好,就写这么多吧。其实当下最重要的策略与行动计划是:好好分析一下自己的长与短,认真规划一下自己的未来,不管未来的路多难,打造自己的核心竞争力才是人间正道。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1666752, encodeId=188f1666e5245, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Thu Oct 22 00:59:00 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992257, encodeId=f8d3199225e6b, content=<a href='/topic/show?id=7e5a492636a' target=_blank style='color:#2F92EE;'>#应对策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49263, encryptionId=7e5a492636a, topicName=应对策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Fri Jan 22 06:59:00 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661271, encodeId=2efa16612e1d3, content=<a href='/topic/show?id=3c979005532' target=_blank style='color:#2F92EE;'>#行动计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90055, encryptionId=3c979005532, topicName=行动计划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aecd25252713, createdName=12498474m38暂无昵称, createdTime=Mon Aug 17 22:59:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409989, encodeId=61cc1409989ae, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Feb 13 23:59:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443619, encodeId=3b6f144361979, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Feb 13 23:59:00 CST 2020, time=2020-02-13, status=1, ipAttribution=)]
    2020-10-22 fengyqf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1666752, encodeId=188f1666e5245, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Thu Oct 22 00:59:00 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992257, encodeId=f8d3199225e6b, content=<a href='/topic/show?id=7e5a492636a' target=_blank style='color:#2F92EE;'>#应对策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49263, encryptionId=7e5a492636a, topicName=应对策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Fri Jan 22 06:59:00 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661271, encodeId=2efa16612e1d3, content=<a href='/topic/show?id=3c979005532' target=_blank style='color:#2F92EE;'>#行动计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90055, encryptionId=3c979005532, topicName=行动计划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aecd25252713, createdName=12498474m38暂无昵称, createdTime=Mon Aug 17 22:59:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409989, encodeId=61cc1409989ae, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Feb 13 23:59:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443619, encodeId=3b6f144361979, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Feb 13 23:59:00 CST 2020, time=2020-02-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1666752, encodeId=188f1666e5245, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Thu Oct 22 00:59:00 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992257, encodeId=f8d3199225e6b, content=<a href='/topic/show?id=7e5a492636a' target=_blank style='color:#2F92EE;'>#应对策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49263, encryptionId=7e5a492636a, topicName=应对策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Fri Jan 22 06:59:00 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661271, encodeId=2efa16612e1d3, content=<a href='/topic/show?id=3c979005532' target=_blank style='color:#2F92EE;'>#行动计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90055, encryptionId=3c979005532, topicName=行动计划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aecd25252713, createdName=12498474m38暂无昵称, createdTime=Mon Aug 17 22:59:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409989, encodeId=61cc1409989ae, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Feb 13 23:59:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443619, encodeId=3b6f144361979, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Feb 13 23:59:00 CST 2020, time=2020-02-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1666752, encodeId=188f1666e5245, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Thu Oct 22 00:59:00 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992257, encodeId=f8d3199225e6b, content=<a href='/topic/show?id=7e5a492636a' target=_blank style='color:#2F92EE;'>#应对策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49263, encryptionId=7e5a492636a, topicName=应对策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Fri Jan 22 06:59:00 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661271, encodeId=2efa16612e1d3, content=<a href='/topic/show?id=3c979005532' target=_blank style='color:#2F92EE;'>#行动计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90055, encryptionId=3c979005532, topicName=行动计划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aecd25252713, createdName=12498474m38暂无昵称, createdTime=Mon Aug 17 22:59:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409989, encodeId=61cc1409989ae, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Feb 13 23:59:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443619, encodeId=3b6f144361979, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Feb 13 23:59:00 CST 2020, time=2020-02-13, status=1, ipAttribution=)]
    2020-02-13 cathymary
  5. [GetPortalCommentsPageByObjectIdResponse(id=1666752, encodeId=188f1666e5245, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Thu Oct 22 00:59:00 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992257, encodeId=f8d3199225e6b, content=<a href='/topic/show?id=7e5a492636a' target=_blank style='color:#2F92EE;'>#应对策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49263, encryptionId=7e5a492636a, topicName=应对策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Fri Jan 22 06:59:00 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661271, encodeId=2efa16612e1d3, content=<a href='/topic/show?id=3c979005532' target=_blank style='color:#2F92EE;'>#行动计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90055, encryptionId=3c979005532, topicName=行动计划)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aecd25252713, createdName=12498474m38暂无昵称, createdTime=Mon Aug 17 22:59:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409989, encodeId=61cc1409989ae, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Feb 13 23:59:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443619, encodeId=3b6f144361979, content=<a href='/topic/show?id=eaf6352e26e' target=_blank style='color:#2F92EE;'>#医药代表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35272, encryptionId=eaf6352e26e, topicName=医药代表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Feb 13 23:59:00 CST 2020, time=2020-02-13, status=1, ipAttribution=)]

相关资讯

医药代表的收入,减少了吗?

4+7带量采购给药企带来的震荡此起彼伏,4+7全国扩面紧随其后。带量采购实行以来,怎样改变药企营销呢?

2020医药代表年度报告

昨日,知药客发布《2020医药代表年度报告》,本次调研问卷共收集了6342条有效数据,全面覆盖了全国31个省份(除香港、澳门特别行政区、台湾),其中超过70%的样本来自1年以上的医药代表。本次年度报告从薪酬、工作痛点、工作年限、兼职情况等多个新颖的角度,探索了医药代表的生存现状。▍薪酬稳步上升,这些城市最多就此次报告的整体年薪分布来看,52.17%的医药代表年薪在10-19万,近10%的医药代表年

一个女医药代表的行贿日记;10天内,41名医务人员主动投案!

评:这仅仅是个案。这个个案背后是医药营销模式契待转型,要从传统的带金销售向学术营销转型。医生需要靠提升个人的职业技能和研究技能,获得更高的晋升机会,从而使收入大幅度提升。如果仍然靠回扣,势必在刀尖上行走,十分危险。 女业务员6年“腐蚀”32名医生   9月3日,一桩震动西南小城——贵州省湄潭县医疗系统的腐败窝案尘埃落定,结果显示,医药代表唐芹(化名)在六年的时间里,竟将该县三大公立医院32

两三甲医院,通知医药代表备案

两所三甲医院,通知医药代表备案。

央视曝光!一批医药代表被抓

有药械代表和黑客组队作案了...

医药代表备案证件,重要信息公开了

三甲医院医药代表证,公开了。